The U.S. Centers for Disease Control and Prevention and the Food and Drug Administration announced yesterday that they are jointly recommending a “pause” in the use of the single-dose Johnson & Johnson COVID-19 vaccine. They’re recommending this pause after that six women (out of the almost 7 million persons who got the vaccine) developed rare blood clots within a week or two, with one of them dying and one in critical condition.
That, my friends, makes developing a blood clot post-vaccine less likely than being struck by lightning.
Still, the two agencies are recommending the pause out of an “abundance of caution” while a thorough review is being conducted.
Wrong.
Bad idea.
In a country where there is so much vaccine hesitancy already, making an issue out of this will just compound the problem.
We already had the previous problem with AstraZeneca and their vaccine, and the question of link to blood clots, which risk was also found to be incredibly small. Better that one or two people die of blood clots — which may or may not be related to the vaccine — than that thousands more die of Covid while hesitating to get vaccinated.
I mean they should go ahead and conduct their investigation, and do it as intensely and quickly as possible, but don’t pause the vaccine roll-out, and don’t scare more Americans unnecessarily.
Let’s keep things moving, for crying out loud.
I have to disagree with this one. The blood clot issue is extremely rare, and although it has only happened six times, all six have been women. That’s enough for me to be very wary, and I’m glad they’re taking it seriously and reevaluating thaw J&J vaccine.
Sorry, didn’t mean to be anonymous…
Bonnie Kraft